NCT00442793
Completed
Phase 3
A Randomized, Open Label Study Comparing the Effect of Mircera and Epoetin Beta on Hemoglobin Response in Patients With Chronic Kidney Disease Who Are on Dialysis
ConditionsAnemia
Overview
- Phase
- Phase 3
- Intervention
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Conditions
- Anemia
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 265
- Primary Endpoint
- Hb response rate
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This 2 arm study will compare the effect on hemoglobin response of Mircera and epoetin beta, in patients with chronic renal anemia who are on dialysis. Eligible patients will be randomized to receive either Mircera (0.4 micrograms/kg i.v. every 2 weeks) or epoetin beta (3 times weekly, according to approved labelling). The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Investigators
Eligibility Criteria
Inclusion Criteria
- •adult patients, \>=18 years of age;
- •chronic renal anemia requiring dialysis;
- •maintenance hemodialysis or peritoneal dialysis for \>=2 weeks before and during screening;
- •adequate iron status.
Exclusion Criteria
- •previous epoetin treatment within 8 weeks prior to screening;
- •failing renal graft in place;
- •bleeding episode necessitating transfusion within 8 weeks prior to screening;
- •poorly controlled hypertension;
- •previous treatment with Mircera.
Arms & Interventions
1
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
2
Intervention: Epoetin beta
Outcomes
Primary Outcomes
Hb response rate
Time Frame: Weeks 0-24
Change in Hb concentration between baseline and evaluation period
Time Frame: Months 4-6
Secondary Outcomes
- Hb over time(Throughout study)
- Serum concentration of Mircera(Throughout study)
- Time to Hb response(Throughout study)
- RBC transfusions(Weeks 0-24)
- AEs, laboratory parameters, vital signs(Throughout study)
Similar Trials
Terminated
Phase 3
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.AnemiaNCT00454246Hoffmann-La Roche111
Completed
Phase 3
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis PatientsAnemiaNCT00394953Hoffmann-La Roche490
Terminated
Phase 2
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving ChemotherapyNeoplasmsAnemiaCancerNCT00386152Johnson & Johnson Pharmaceutical Research & Development, L.L.C.235
Completed
Phase 4
Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced AnemiaAnemiaChemotherapyNCT00315484Ortho Biotech Products, L.P.358
Completed
Phase 3
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.AnemiaNCT00442702Hoffmann-La Roche228